Department of Pharmacology, Faculty of Medicine and Dentistry, Pomeranian Medical University, Powstancow Wlkp 72, 70-111 Szczecin, Poland.
Institute of Pharmacology and Toxicology, Faculty of Medicine, Rostock University Medical Center, 18057 Rostock, Germany.
Biomed Pharmacother. 2021 Nov;143:112125. doi: 10.1016/j.biopha.2021.112125. Epub 2021 Aug 30.
Emerging information suggests that pathology of the kidney may not only affect expression and function of membrane transporters in the organ, but also in the gastrointestinal tract and the liver. Transporter dysfunction may cause effects on handling of drug as well as endogenous compounds with subsequent clinical consequences. A literature search was conducted on Ovid and PubMed databases to select relevant in vitro, animal and human studies that have reported expression, protein abundance and function of the gastrointestinal and liver localized ABC transporters and SLC carriers in kidney dysfunction or uremia states. The altered function of drug transporters in the liver and intestines in kidney failure subjects may provide compensatory activity in handling endogenous compounds (e.g. uremic toxins), which is expected to affect drug pharmacokinetics and local drug actions.
新兴信息表明，肾脏的病理变化不仅可能影响器官中膜转运蛋白的表达和功能，还可能影响胃肠道和肝脏中的膜转运蛋白。转运蛋白功能障碍可能会影响药物以及内源性化合物的处理，从而产生临床后果。在 Ovid 和 PubMed 数据库上进行了文献检索，以选择报告了在肾功能障碍或尿毒症状态下胃肠道和肝脏定位的 ABC 转运体和 SLC 载体的表达、蛋白丰度和功能的相关体外、动物和人体研究。在肾衰竭患者中，肝脏和肠道中的药物转运体功能改变可能为处理内源性化合物（例如尿毒症毒素）提供代偿性活性，这预计会影响药物的药代动力学和局部药物作用。
